Organ-on-a-chip reveals how SARS-CoV-2 invades blood vessels

Image source: Kyoto University

News • Coronavirus mechanism discovered

Organ-on-a-chip reveals how SARS-CoV-2 invades blood vessels

A research group led by CiRA Junior Associate Professor Kazuo Takayama and Associate Professor Yoshiaki Okada of Osaka University has revealed that SARS-CoV-2 disrupts the vascular endothelial barrier by suppressing the expression of Claudin-5 (CLDN5) to invade the blood vessels.

SARS-CoV-2 infects respiratory epithelial cells and then spreads to other organs via blood vessels. In this case, SARS-CoV-2 crosses the walls of blood vessels (the barrier of vascular endothelial cells) from respiratory organs and enters the blood vessels. However, the mechanism was unknown. The research group created an airway-on-a-chip that mimics respiratory organs consisting of airway epithelial cells and vascular endothelial cells. Using the device, they found that SARS-CoV-2 disrupts the vascular endothelial barrier by suppressing the expression of CLDN5, a protein involved in adhesive junctions between vascular endothelial cells, and by subsequently weakening the vascular endothelial cadherin-mediated junctions. The team confirmed that CLDN5 gene and protein expression levels were decreased in the lungs of a patient with Covid-19. They also demonstrated that increasing CLDN5 expression in vascular endothelial cells by gene transfer or small molecule drugs (fluvastatin) suppressed SARS-CoV-2-induced vascular endothelial barrier disruption. 

The results of this study were published in Science Advances.

These results indicate that suppression of CLDN5 expression is an essential mechanism for SARS-CoV-2-induced vascular endothelial barrier disruption, which increases the severity of Covid-19. The findings also indicate that up-regulation of CLDN5 expression is a new therapeutic strategy against Covid-19. 

The airway-on-a-chip technology, which can be used to reproduce the respiratory pathology of Covid-19 and search for therapeutic agents, is a promising tool for elucidating the pathogenesis of severe respiratory tract infections including Covid-19 and developing therapeutic drugs in the future. 


Source: Kyoto University

29.09.2022

Read all latest stories

Related articles

Photo

News • Deep mutational scanning for SARS-CoV-2

Preparing rapid tests for future coronavirus variants

How can rapid antigen tests be adjusted to reliably detect future variants of SARS-CoV-2? A research team funded by the National Institutes of Health is currently working on finding an answer.

Photo

Video • New virus 2019-nCoV

Scientists grow Wuhan coronavirus in the lab

Scientists from The Peter Doherty Institute for Infection and Immunity in Melbourne have successfully grown the Wuhan coronavirus (also known as SARS-CoV-2) from a patient sample, which will provide…

Photo

Sponsored • Disease management

Multiplex Testing: A Solution to Manage Surge in Respiratory Illnesses as Concerns over “Multi-demic” Rise

Eunsin Bae, M.D. specializes in laboratory medicine and leads the Institute of Clinical Research at Seegene Inc. Her research focuses on microbiology, molecular biology, and hematology. Dr. Bae is…

Related products

Siemens Healthineers – Fast Track Real-time PCR assays

Infectious Disease

Siemens Healthineers – Fast Track Real-time PCR assays

Siemens Healthineers
CliniSys – Anatomical Pathology Laboratory

Information Technology

CliniSys – Anatomical Pathology Laboratory

CliniSys Deutschland GmbH
CliniSys – Clinical Laboratory

LIS / Middleware / POCT

CliniSys – Clinical Laboratory

CliniSys Deutschland GmbH
CliniSys – Genetics Laboratory

LIS / Middleware / POCT

CliniSys – Genetics Laboratory

CliniSys Deutschland GmbH
CliniSys – Order & Results Management

LIS / Middleware / POCT

CliniSys – Order & Results Management

CliniSys Deutschland GmbH
Subscribe to Newsletter